Top

World Journal of Surgery

Published in:

01-10-2011

Short-Term and Mid-Term Control of Type 2 Diabetes Mellitus by Laparoscopic Sleeve Gastrectomy with Ileal Interposition

Authors: Augusto Tinoco, Luciana El-Kadre, Livia Aquiar, Renam Tinoco, Paulo Savassi-Rocha

Published in: World Journal of Surgery | Issue 10/2011

Abstract

Background

Standard surgical procedures used for the treatment of morbid obesity constitute optional treatments for type 2 diabetes mellitus (T2DM). The aim of the present study was to evaluate the short- and mid-term effects of laparoscopic sleeve gastrectomy (SG) with ileal interposition (II) in T2DM patients (n = 30).

Methods

The variables investigated were the feasibility of the procedure, remission/alleviation of the disease, morbidity, mortality, and weight loss. Patients were followed during a period of 6–18 months after surgery.

Results

The average time required for the surgical procedure was 181.47 ± 53.23 min, and the mean duration of postoperative hospital stay was 3.17 ± 0.79 days. There were no intraoperative complications, and none of the patients required conversion to open surgery. Postoperatively, all patients experienced a significant weight loss: i.e., the mean body mass index (BMI) values prior to and following surgery were significantly different (P = 0.0001). Postoperative levels of glycosylated hemoglobin, fasting glucose, and fructosamine were significantly reduced (P = 0.0001, 0.0001, and 0.0004, respectively) from those detected prior to surgery. Remission of T2DM was observed in 80% of the patients over the follow-up period, and these subjects no longer required treatment with hypoglycemic drugs or diet. The remaining 20% of patients presented significant improvement in their condition but needed an oral hypoglycemic medication.

Conclusions

Adequate glycemic control, adjustable weight loss, and absence of nutritional deficiencies were the main benefits offered by the surgical intervention. The results indicate that SG/II treatment could be a promising alternative for patients with T2DM.

Pinkey J (2010) Bariatric surgery for diabetes: gastric banding is simple and safe. Br J Diabetes Vasc Dis 10:139–142CrossRef

Buchwald H, Estok R, Fahrbach K et al (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122:248–256PubMedCrossRef

Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG et al (2003) Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 52:1098–1103PubMedCrossRef

Gautier JF, Fetita S, Sobngwi E et al (2005) Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31:233–242PubMedCrossRef

Atkinson RL, Brent EL, Wagner BS et al (1983) Energy balance and regulation of body weight after intestinal bypass surgery in rats. Am J Physiol 245:R658–R663PubMed

Kjems LL, Holst JJ, Volund A et al (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386PubMedCrossRef

Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929–2940PubMedCrossRef

Irwin N, Gault VA, Green BD et al (2004) Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol Chem 385:845–852PubMedCrossRef

Gault VA, Irwin N, Green BD et al (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436–2446PubMedCrossRef

10.

Ferrannini E, Cobelli C (1987) The kinetics of insulin in man. I. General aspects. Diabetes Metab Rev 3:335–363PubMedCrossRef

11.

Vilsboll T, Holst JJ (2004) Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:357–366PubMedCrossRef

12.

Aasheim ET, Hofso D, Hjelmesaeth J et al (2008) Peripheral neuropathy and severe malnutrition following duodenal switch. Obes Surg 18:1640–1643PubMedCrossRef

13.

Varma S, Baz W, Badine E et al (2008) Need for parenteral iron therapy after bariatric surgery. Surg Obes Relat Dis 4:715–719PubMedCrossRef

14.

Shikora SA, Kim JJ, Tarnoff ME (2007) Nutrition and gastrointestinal complications of bariatric surgery. Nutr Clin Pract 22:29–40PubMedCrossRef

15.

El-Kadre L, Rocha PR, de Almeida Tinoco AC et al (2004) Calcium metabolism in pre- and postmenopausal morbidly obese women at baseline and after laparoscopic Roux-en-Y gastric bypass. Obes Surg 14:1062–1066PubMedCrossRef

16.

Strader AD (2006) Ileal transposition provides insight into the effectiveness of gastric bypass surgery. Physiol Behav 88:277–282PubMedCrossRef

17.

DePaula AL, Macedo AL, Schraibman V et al (2009) Hormonal evaluation following laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20–34. Surg Endosc 23:1724–1732PubMedCrossRef

18.

DePaula AL, Macedo AL, Rassi N et al (2008) Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc 22:2670–2678PubMedCrossRef

19.

Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRef

20.

Cummings DE, Weigle DS, Frayo RS et al (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630PubMedCrossRef

21.

Williams D, Cummings D (2005) Regulation of ghrelin in physiologic and pathophysiologic states. J Nutr 135:1320–1325PubMed

22.

DePaula AL, Macedo AL, Rassi N et al (2008) Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 22:706–716PubMedCrossRef

23.

DePaula AL, Macedo AL, Mota BR et al (2009) Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21–29. Surg Endosc 23:1313–1320PubMedCrossRef

24.

American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:62–69CrossRef

25.

American Diabetes Association (2010) Executive summary: standards of medical care in diabetes—2010. Diabetes Care 33:S4–S10CrossRef

26.

Turton MD, O’Shea D, Gunn I et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72PubMedCrossRef

27.

Verdich C, Flint A, Gutzwiller JP et al (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382–4389PubMedCrossRef

28.

Kastin AJ, Akerstrom V, Pan W (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18:7–14PubMedCrossRef

29.

Nauck MA, Kleine N, Orskov C et al (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741–744PubMedCrossRef

30.

Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929–2940PubMedCrossRef

31.

Buchwald H, Williams SE (2004) Bariatric surgery worldwide 2003. Obes Surg 14:1157–1164PubMedCrossRef

32.

Wittgrove AC, Clark GW (2000) Laparoscopic gastric bypass, Roux-en-Y—500 patients: technique and results, with 3–60 month follow-up. Obes Surg 10:233–239PubMedCrossRef

33.

Sugerman HJ, Wolfe LG, Sica DA et al (2003) Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 237:751–756PubMed

34.

Schauer PR, Burguera B, Ikramuddin S et al (2003) Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238:467–484PubMed

35.

Kim S, Richards WO (2010) Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann Surg 251:1049–1055PubMedCrossRef

36.

Torquati A, Lutfi R, Abumrad N et al (2005) Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 9:1112–1116PubMedCrossRef

37.

DiGiorgi M, Rosen DJ, Choi JJ et al (2010) Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 6:249–253PubMedCrossRef

38.

Chikunguwo SM, Wolfe LG, Dodson P et al (2010) Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 6:254–259PubMedCrossRef

39.

Rubino F (2009) Access to bariatric surgery and patients with diabetes. JAMA 302:1055–1056PubMedCrossRef

40.

Buchwald H, Oien DM (2009) Metabolic/bariatric surgery worldwide 2008. Obes Surg 19:1605–1611PubMedCrossRef

41.

Buchwald H, Williams SE (2006) Bariatric surgery training in the United States. Surg Obes Relat Dis 2:52–55PubMedCrossRef

42.

Todkar JS, Shah SS, Shah PS et al (2010) Long-term effects of laparoscopic sleeve gastrectomy in morbidly obese subjects with type 2 diabetes mellitus. Surg Obes Relat Dis 6:142–145PubMedCrossRef

43.

Rosenthal R, Li X, Samuel S et al (2009) Effect of sleeve gastrectomy on patients with diabetes mellitus. Surg Obes Relat Dis 5:429–434PubMedCrossRef

44.

DePaula AL, Stival AR, DePaula CC et al (2010) Impact on dyslipidemia of the laparoscopic ileal interposition associated to sleeve gastrectomy in type 2 diabetic patients. J Gastrointest Surg 14:1319–1325PubMedCrossRef

45.

Kumar KV, Ugale S, Gupta N et al (2009) Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes Technol Ther 11:785–789PubMedCrossRef

46.

Pournaras DJ, Jafferbhoy S, Titcomb DR et al (2010) Three hundred laparoscopic Roux-en-Y gastric bypasses: managing the learning curve in higher risk patients. Obes Surg 20:290–294PubMedCrossRef

47.

Suter M, Giusti V, Heraief E et al (2003) Laparoscopic Roux-en-Y gastric bypass: initial 2-year experience. Surg Endosc 17:603–609PubMedCrossRef

48.

Strader AD, Vahl PV, Ronald J et al (2004) Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288:447–453CrossRef

49.

Strader AD (2006) Ileal transposition provides insight into the effectiveness of gastric bypass surgery. Physiol Behav 88:277–282PubMedCrossRef

50.

Strader AD, Clausen TR, Goodin SZ et al (2009) Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg 19:96–104PubMedCrossRef

51.

Strader AD, Vahl TP, Jandacek RJ et al (2005) Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288:E447–E453PubMedCrossRef

52.

Patriti A, Annetti C, Sidoni A et al (2007) How the hindgut can cure type 2 diabetes: ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery 142:74–85PubMedCrossRef

53.

Patriti A, Facchiano E, Annetti C et al (2005) Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 15:1258–1264PubMedCrossRef

54.

Koopmans HS, Sclafani A, Fichtner C et al (1982) The effects of ileal transposition on food intake and body weight loss in VMH-obese rats. Am J Clin Nutr 35:284–293PubMed

55.

Boza C, Gagner M, Devaud N et al (2008) Laparoscopic sleeve gastrectomy with ileal transposition (SGIT): a new surgical procedure as effective as gastric bypass for weight control in a porcine model. Surg Endosc 22:1029–1034PubMedCrossRef

Title: Short-Term and Mid-Term Control of Type 2 Diabetes Mellitus by Laparoscopic Sleeve Gastrectomy with Ileal Interposition
Authors: Augusto Tinoco
Luciana El-Kadre
Livia Aquiar
Renam Tinoco
Paulo Savassi-Rocha
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 10/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-011-1188-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Short-Term and Mid-Term Control of Type 2 Diabetes Mellitus by Laparoscopic Sleeve Gastrectomy with Ileal Interposition

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2011

Transabdominal Preperitoneal Repair for Obturator Hernia

Note on Hemostatic Devices in Liver Surgery: Reply

Outcomes of Severely Injured Adult Trauma Patients in an Australian Health Service: Does Trauma Center Level Make a Difference?

Should We Promote “Increasing Donor Body Weight To Prevent Small-for-Size Syndrome in Living Donor Liver Transplantation”?

Prognostic Factors Affecting Postmastectomy Locoregional Recurrence in Patients with Early Breast Cancer: Are Intrinsic Subtypes Effective?

The Methods of Reconstruction of Pancreatic Digestive Continuity After Pancreaticoduodenectomy: A Meta-Analysis of Randomized Controlled Trials